Dow Gains Over 100 Points; AutoZone Posts Upbeat Earnings
U.S. stocks rose Tuesday: Dow +0.24%, Nasdaq +0.39%, S&P 500 +0.18%. Communication services led; energy fell. AutoZone beat earnings; oil dropped 2.4%.
Stocks · News reference
Vicor jumped 11% premarket after raising Q3 growth guidance above 20%; TOPS, FBGL and QNME led other gainers.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
U.S. stocks rose Tuesday: Dow +0.24%, Nasdaq +0.39%, S&P 500 +0.18%. Communication services led; energy fell. AutoZone beat earnings; oil dropped 2.4%.
Lobo Technologies shares surged 32% premarket after a narrower H1 loss and higher sales; several small caps rallied while others fell sharply.
Black Titan Corporation (NASDAQ:BTTC) ("Black Titan" or the "Company") today announced that on September 2, 2026, it received a written notification (the "Nasdaq Notice") from the Listing
The global paternity and relationship testing market is expanding beyond traditional paternity testing into broader applications including maternity, grandparent, sibling, and infidelity testing. The market is projected to grow from $1.08 billion in 2025 to $1.45 billion by 2030 at a CAGR of 6.1%. Growth is driven by increased direct-to-consumer genetic testing accessibility, cultural shifts in family definitions, and demand for legally recognized testing. However, the market faces challenges from increased competition, lower pricing, and regulatory complexity across jurisdictions.
Quest Diagnostics (DGX) is experiencing growth across physician, hospital, and consumer channels, driven by customer wins and an expanding advanced diagnostics portfolio delivering double-digit growth. The company targets 3% annual cost savings through AI and automation initiatives. However, reimbursement uncertainty, cost pressures, and elevated debt of $5.63 billion remain concerns that could impact margins and financial flexibility.
CMS proposes 2027 Medicare lab rates, estimating $1 billion in annual taxpayer savings as payments align with private rates.